today announced that the first patients in Cohort 1 of its Phase 1a clinical trial of MIB-725 have received their initial doses. MIB-725 is a new, proprietary investigational drug that has been ...

Discover Fractyl Health's Q1 2025 earnings call insights—accelerated trial enrollments, robust patient demand, and exciting data milestones.

today announced the first patients have been dosed in the final cohort of its Phase 1b clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson's disease. Commenting ...